Evoke Pharma and EVERSANA Showcase GIMOTI Results

Evoke Pharma, in collaboration with EVERSANA, presented real-world data on GIMOTI® nasal spray's effectiveness for diabetic gastroparesis (DGP) patients who use GLP-1 agonists, a medication type that may worsen DGP symptoms. This retrospective study, shared at the ACG 2024 Annual Meeting, highlighted that GIMOTI users had significantly fewer emergency and outpatient visits compared to those on oral metoclopramide, suggesting the nasal spray's efficacy in managing symptoms without relying on delayed gastric emptying.

The findings included a substantial reduction in healthcare resource use (HRU) for patients with GLP-1 prescriptions, with GIMOTI reducing ED visits by up to 91% and hospital outpatient visits by nearly 89% in some cases. This data builds on prior evidence, suggesting that GIMOTI offers a non-oral option with fewer absorption issues, proving particularly advantageous for those with gastroparesis-related complications.

Medical professionals, like Dr. Michael Cline of the Cleveland Clinic, see these outcomes as promising for DGP patients on GLP-1 therapies. The nasal formulation bypasses gastric processes, providing symptom relief without the limitations of oral drugs. Evoke’s studies, including previous presentations, suggest GIMOTI may significantly lower healthcare costs and improve life quality for this growing patient group.